Supplementary Tables – Real-world treatment of patients with palbociclib for HR+/HER2– advanced/metastatic breast cancer: the Europe IRIS study

<b>Supplementary Table S1. </b>Patient inclusion criteria<b> </b> <b>Supplementary Table S2. </b>Therapeutic indications for IBRANCE (palbociclib) in the EU <b>Supplementary Table S3. </b>Patient demographics and clinical characteristics for the nine individual EU countries<b></b> <b>Supplementary Table S4. </b>Palbociclib treatment patterns for the nine individual EU countries <b>Supplementary Table S5. </b>Response to palbociclib treatment for the nine individual EU countries Real-world treatment of patients with palbociclib for HR+/HER2– advanced/metastatic breast cancer: the Europe IRIS study